Posted in | News | Nanomedicine

C&EN Article Details the Challenges on the Road to Generic Nanodrugs

Nanomedicine is offering patients a growing arsenal of therapeutic drugs for a variety of diseases but often at a cost of thousands of dollars a month. Generics could substantially reduce the price tag for patients -- if only there were a well-defined way to make and regulate them. An article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, details the challenges on the road to generic nanodrugs.

Matt Davenport, a C&EN contributing editor, points out that in small-molecule therapeutics -- aspirin, for example -- the active ingredient is the primary concern of regulators. For these drugs, making generic versions is a relatively straightforward process. Nanomedicine, on the other hand, is far more complicated. It often involves packaging an active ingredient inside engineered delivery systems made out of materials such as lipids, polymers or carbohydrates. Even slight changes to a nanodrug's structure can result in a different toxicity level.

To date, the Food and Drug Administration (FDA) has approved dozens of nanodrugs although it has no formal regulatory definition for what a nanodrug is. Such a definition would be a first step toward clearer regulations.

The agency currently examines each nano therapeutic on a case-by-case basis and offers guidance to drug makers that is nonbinding for now. Still, in 2013, the FDA signed off on what many consider to be the first generic therapeutic in this category, but no one is sure when the next approval might come.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    American Chemical Society. (2019, February 11). C&EN Article Details the Challenges on the Road to Generic Nanodrugs. AZoNano. Retrieved on October 13, 2024 from https://www.azonano.com/news.aspx?newsID=31497.

  • MLA

    American Chemical Society. "C&EN Article Details the Challenges on the Road to Generic Nanodrugs". AZoNano. 13 October 2024. <https://www.azonano.com/news.aspx?newsID=31497>.

  • Chicago

    American Chemical Society. "C&EN Article Details the Challenges on the Road to Generic Nanodrugs". AZoNano. https://www.azonano.com/news.aspx?newsID=31497. (accessed October 13, 2024).

  • Harvard

    American Chemical Society. 2019. C&EN Article Details the Challenges on the Road to Generic Nanodrugs. AZoNano, viewed 13 October 2024, https://www.azonano.com/news.aspx?newsID=31497.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.